A company building a pipeline of small molecule drugs targeting novel proteins across the DNA mismatch repair (pathway) has announced a further extension to its series B financing round.
acnnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from acnnewswire.com Daily Mail and Mail on Sunday newspapers.
The U.S. company Rome Therapeutics plans to use the proceeds of its $72 million Series B round to take an experimental autoimmune disease treatment through early clinical testing.
Actimed Therapeutics Ltd will put some of its additional funding of £4.75 million ($6 million) towards its attempt to provide the world’s first cure for cancer cachexia.